Skip to Main Content

Author Details

Stephen G O'Brien
Newcastle University
1993
72
32
PMIDPaper TitleJournal TitlePublished Year
34993961The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.Br J Haematol2022
35176378A collective statement in support of saving pangolins.Sci Total Environ2022
31448733Trial re-investment to build better research for better impact.Lancet2019
31201085De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.Lancet Haematol2019
30206237Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.Cell Death Dis2018
27891583The use of anthracyclines in the treatment of endemic Burkitt lymphoma.Br J Haematol2017
28273028Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.N Engl J Med2017
28566209De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.Lancet Haematol2017
25250944PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.Am J Hematol2015
24628491Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia.Br J Haematol2014
23380743Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.Blood2013
24117365A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.Br J Haematol2013
21844874KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.Leukemia2012
22822001Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.Blood2012
22645182Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.Blood2012
19837975A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.Blood2010
20679528Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).Blood2010
20739956Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.Leukemia2010
20305143Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.Haematologica2010
19282833Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia2009
19648168High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.Haematologica2009
19117345Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.Cancer2009
18048643Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Blood2008
18256322Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.Blood2008
17715389Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.Blood2007
18056852Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia.Blood2007
17606448An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.Haematologica2007
17634544Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.Clin Cancer Res2007
16706941Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.Clin Lab Haematol2006
17151364Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med2006
16151465A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.Leukemia2005
15036936Clinical results with imatinib in chronic myeloid leukaemia.Leuk Res2004
15561681Chronic myelogenous leukemia and myeloproliferative disease.Hematology Am Soc Hematol Educ Program2004
15271395Imatinib therapy in chronic myeloid leukemia.Hematol Oncol Clin North Am2004
15229152Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.Clin Chem2004
12775739Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.J Clin Oncol2003
12886230Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.Leukemia2003
12869491Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.Blood2003
14612892Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.Br J Cancer2003
12637609Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med2003
12668652Practical management of patients with chronic myeloid leukemia receiving imatinib.J Clin Oncol2003
12783372Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.Semin Hematol2003
11870241Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med2002
12200353A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.Blood2002
12358935Position paper on imatinib mesylate in chronic myeloid leukaemia.Br J Haematol2002
12358909Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.Br J Haematol2002
12412577Managing cutaneous reactions to imatinib therapy.Blood2002
12446421Chronic myelogenous leukemia.Hematology Am Soc Hematol Educ Program2002
11964320Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.Blood2002
12076575Not so NICE for CML.Lancet2002
  • 1 - 50 of 72

Recommended Authors

Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 8
Patricia Kropf
Novant Health Cancer Institute - Elizabeth
Career Start Year 2009
Number of shared co-authors 11
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 6
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 2
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 11
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 3
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 7
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 12
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 12
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 8
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 8
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Career Start Year 1998
Number of shared co-authors 3
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 7
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 4
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 9
Guillermo Garcia-Manero
MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 11
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 10
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 7
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 6
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 8
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 0
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 4
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 12
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 11
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 4
Neil P Shah
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 14
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 8
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 8

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 16
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 8
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 6
Lucy C Crossman
Oregon Health & Science University Cancer Institute
Co-authored papers 4
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Junia V Melo
University of Adelaide
Co-authored papers 3
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 3
Jorge Cortes
Georgia Cancer Center
Co-authored papers 3
Moshe Talpaz
University of Michigan Rogel Cancer Center.
Co-authored papers 2
Thoralf Lange
Hospital Weissenfels
Co-authored papers 2
Jamshid S Khorashad
Institute of Cancer Research
Co-authored papers 2
Dietger Niederwieser
University of Leipzig
Co-authored papers 2
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 2
Yaron Turpaz
Pte. Ltd.
Co-authored papers 1
Siew Woh Choo
Co-authored papers 1
Heike Bickeb??ller
University Medical Center Goettingen
Co-authored papers 1
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 1
Raji Pillai
Jawaharlal Institute of Post-graduate Medical Education and Research
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Anne M Dickinson
Translational and Clinical Research Institute, Newcastle University
Co-authored papers 1
Dong Wook Kim
Yonsei University College of Medicine, Republic of Korea S. Biomedics Co.
Co-authored papers 1
Lucy C Pemberton
Southern District Health Board, Dunedin Hospital
Co-authored papers 1
Christopher S Foster
The Institute of Cancer Research
Co-authored papers 1
Ravi Bhatia
University of Alabama at Birmingham
Co-authored papers 1
Janice Gabrilove
Co-authored papers 1
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 1
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Guanghou Shui
Co-authored papers 1
Release 1.2